AesMed is pleased to announce the successful completion of its participation in KIMES 2026 (The 41st Korea International Medical & Hospital Equipment Show), held at COEX, Seoul.
As one of Asia’s leading medical exhibitions, KIMES 2026 brought together global healthcare professionals, industry leaders, and innovative companies to showcase the latest advancements in medical technology.
Showcasing Advanced Solutions for Alopecia Care
At this year’s exhibition, AesMed presented its latest innovations in hair-loss treatment and regenerative scalp care, receiving strong interest from both domestic and international visitors.
[Key highlights included:]
CytoMesopecia – Cytokines Mesotherapy for Alopecia
– AesMed’s structured clinical framework designed to translate cytokine science into practical treatment protocols
AGF39 Cytokine Solution
– A proprietary formulation developed for professional mesotherapy, widely adopted in hair-loss treatment clinics across multiple countries
4th Generation Advance Follicle Shampoo
– Designed with a Nonionic Surfactant base, offering mild, biocompatible cleansing suitable for sensitive scalp conditions while supporting clinical treatments
Visitors to Booth A816 had the opportunity to explore how these solutions are integrated into real-world clinical settings, enhancing treatment outcomes through a science-based approach.eal-world clinical settings, enhancing treatment outcomes through a science-based approach.
Strengthening Global Connections
Throughout the exhibition, AesMed engaged with:
• Hair-loss specialists and dermatologists
• Medical device distributors and global buyers
• Industry professionals seeking advanced treatment solutions
These interactions provided valuable opportunities to discuss clinical applications, partnership potential, and global market expansion.
Looking Ahead: Expanding Global Presence
Building on the success of KIMES 2026, AesMed plans to further strengthen its global business strategy by expanding collaboration with international partners and increasing the accessibility of its solutions worldwide.
AesMed remains committed to advancing the field of alopecia treatment through scientific innovation, clinical validation, and global cooperation.
Conclusion
KIMES 2026 served as an important platform for AesMed to demonstrate its expertise and vision in regenerative hair-loss treatment. The strong interest and positive feedback received reaffirm the growing demand for cytokines-based therapeutic approaches.
AesMed will continue to lead innovation in this field and support healthcare professionals in delivering more effective and sustainable solutions for patients.
Learn more about AesMed:
